NFKB1 and neoplasm: Based on the TAM-PA and TAM-PS341 combinations evaluated here, a TAM-sensitizing drug dose affecting a high-risk ER-positive breast cancer would be expected to restore ER-NCoR binding and could be monitored during therapy by tumor reduction in the validated NFκB and AP-1 gene expression signature.